Easy to see

Full-length visibility provides real-time visual feedback for additional control

Increased clot integration

360° of consistently large double-wide cells

High radial force at small diameters

High radial force at small diameters as Trevo™ Retrievers integrate clot; low post-integration radial force designed for atraumatic retrieval

1. The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should start within 6 hours of symptom onset.

2. The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

3. The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller core infarcts (0-50cc for age <80 years, 0-20cc for age ≥80 years). Endovascular therapy with the device should start within 6-24 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy

• Store in cool, dry, dark place.

• Do not use open or damaged packages.

• Use by “Use By” date.

• Exposure to temperatures above 54°C (130°F) may damage device and accessories. Do not autoclave.

• Do not expose Retriever to solvents.

• Use Retriever in conjunction with fluoroscopic visualization and proper anti-coagulation agents.

• To prevent thrombus formation and contrast media crystal formation, maintain a constant infusion of appropriate flush solution between guide catheter and Microcatheter and between Microcatheter and Retriever or guidewire.

• Do not attach a torque device to the shaped proximal end of DOC Compatible Retriever. Damage may occur, preventing ability to attach DOC Guide Wire Extension

Procedures requiring percutaneous catheter introduction should not be attempted by physicians unfamiliar with possible complications which may occur during or after the procedure. Possible complications include, but are not limited to, the following:

• air embolism

• hematoma or hemorrhage at puncture site

• infection

• distal embolization

• pain/headache

• vessel spasm • thrombosis

• dissection

• perforation

• emboli

• acute occlusion

• ischemia

• intracranial hemorrhage

• false aneurysm formation

• neurological deficits including stroke

• death Use of device requires fluoroscopy which presents potential risks to physicians and patients associated with x-ray exposure. Possible risks include, but are not limited to, the following:

• alopecia,

• burns ranging in severity from skin reddening to ulcers,

• cataracts,

• delayed neoplasia